Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.47 |
| ▸ | ELANE | P08246 | 3/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | MMP12 | P39900 | 1/20 | 0.40 |
| ▸ | MMP13 | P45452 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28171481 | 0.86 | ELANE (0.44) | FFAR1ELANECYP19A1ALDH1A1ATM | |
| SCHEMBL27581241 | 0.86 | ELANE (0.59) | FFAR1ELANECYP19A1ALDH1A1ATM | |
| SCHEMBL666155 | 0.83 | POLB (0.47) | ELANECYP19A1ALDH1A1HSD17B10ALOX15 | |
| SCHEMBL27683318 | 0.83 | TRPA1 (0.45) | FFAR1ELANECYP19A1ALDH1A1ATM | |
| SCHEMBL27765405 | 0.83 | TRPA1 (0.45) | FFAR1ELANECYP19A1ALDH1A1ATM | |
| SCHEMBL6237740 | 0.83 | ELANE (0.46) | FFAR1ELANECYP19A1ALDH1A1LMNA | |
| SCHEMBL1870721 | 0.81 | LMNA (0.50) | ELANECYP19A1ALDH1A1HSD17B10ATM | |
| SCHEMBL15870694 | 0.81 | ELANE (0.41) | FFAR1ELANECYP19A1ALDH1A1ATM | |
| SCHEMBL6566817 | 0.81 | L3MBTL1 (0.44) | FFAR1ELANECYP19A1ALDH1A1ATM | |
| SCHEMBL27581304 | 0.81 | ELANE (0.41) | FFAR1ELANECYP19A1ALDH1A1ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2150111-B1 | SUBSTITUTED 1,3-DIOXANES USEFUL AS PPAR MODULATORS | EVOLVA SA (CH) | 2016-10-19 | — | — | EP | disclosed |
| US-20160193179-A1 | Treatment of Cardiovascular Risk in Diabetic Patients | SAKARIASSEN KJELL STEINAR (IT) | 2016-07-07 | — | — | US | disclosed |
| US-20160193179-A1 | Treatment of Cardiovascular Risk in Diabetic Patients | SAKARIASSEN KJELL STEINAR (IT) | 2016-07-07 | — | — | US | disclosed |
| US-9260406-B2 | Substituted 1,3-dioxanes useful as PPAR modulators | EVOLVA SA (CH) | 2016-02-16 | — | — | US | disclosed |
| US-9260406-B2 | Substituted 1,3-dioxanes useful as PPAR modulators | EVOLVA SA (CH) | 2016-02-16 | — | — | US | disclosed |
| WO-2015193630-A1 | TREATMENT OF CARDIOVASCULAR RISK IN PATIENTS WITH CARDIOVASCULAR DISEASE AND/OR DIABETES | EVOLVA SA (CH) | 2015-12-23 | — | — | WO | disclosed |
| US-20150158838-A1 | Prodrugs of Substituted 1,3-Dioxanes and Their Uses | EVOLVA SA (CH) | 2015-06-11 | — | — | US | disclosed |
| US-20150158838-A1 | Prodrugs of Substituted 1,3-Dioxanes and Their Uses | EVOLVA SA (CH) | 2015-06-11 | — | — | US | disclosed |
| US-8952053-B2 | Prodrugs of substituted 1,3-dioxanes and their uses | EVOLVA SA (CH) | 2015-02-10 | — | — | US | disclosed |
| US-8952053-B2 | Prodrugs of substituted 1,3-dioxanes and their uses | EVOLVA SA (CH) | 2015-02-10 | — | — | US | disclosed |
| US-20120142766-A1 | SUBSTITUTED 1,3-DIOXANES AND THEIR USES | EVOLVA SA (CH) | 2012-06-07 | — | — | US | disclosed |
| US-20100273824-A1 | SUBSTITUTED 1,3-DIOXANES AND THEIR USES | EVOLVA SA (CH) | 2010-10-28 | — | — | US | disclosed |
| US-20100273824-A1 | SUBSTITUTED 1,3-DIOXANES AND THEIR USES | EVOLVA SA (CH) | 2010-10-28 | — | — | US | disclosed |
| US-20100168169-A1 | SUBSTITUTED 1,3-DIOXANES USEFUL AS PPAR MODULATORS | EVOLVA SA (CH) | 2010-07-01 | — | — | US | disclosed |
| US-20100168169-A1 | SUBSTITUTED 1,3-DIOXANES USEFUL AS PPAR MODULATORS | EVOLVA SA (CH) | 2010-07-01 | — | — | US | disclosed |
| US-20100087517-A1 | PRODRUGS OF SUBSTITUTED 1,3-DIOXANES AND THEIR USES | EVOLVA SA (CH) | 2010-04-08 | — | — | US | disclosed |
| WO-2008089463-A2 | SUBSTITUTED 1,3-DIOXANES AND THEIR USES | EVOLVA SA (CH) | 2008-07-24 | — | — | WO | disclosed |
| WO-2008089462-A2 | SUBSTITUTED 1,3-DIOXANES AND THEIR USES | EVOLVA SA (CH) | 2008-07-24 | — | — | WO | disclosed |
| WO-2008089464-A1 | PRODRUGS OF SUBSTITUTED 1,3-DIOXANES AND THEIR USES | EVOLVA SA (CH) | 2008-07-24 | — | — | WO | disclosed |
| WO-2008089461-A1 | SUBSTITUTED 1,3-DIOXANES USEFUL AS PPAR MODULATORS | EVOLVA SA (CH) | 2008-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160193179-A1 | Treatment of Cardiovascular Risk in Diabetic Patients | P2RY12, P2RY13, P2RY6 | FFAR1 42/4885ELANE 1466/4885CYP19A1 3114/4885 |
| US-20100087517-A1 | PRODRUGS OF SUBSTITUTED 1,3-DIOXANES AND THEIR USES | TBXA2R, PPARG, PPARA | FFAR1 25/4885ELANE 1101/4885CYP19A1 28/4885 |
| US-20120142766-A1 | SUBSTITUTED 1,3-DIOXANES AND THEIR USES | TBXA2R, PPARG, PPARA | FFAR1 63/4885ELANE 1012/4885CYP19A1 43/4885 |
| US-20100273824-A1 | SUBSTITUTED 1,3-DIOXANES AND THEIR USES | TBXA2R, PPARG, PPARA | FFAR1 63/4885ELANE 1012/4885CYP19A1 43/4885 |
| US-20100168169-A1 | SUBSTITUTED 1,3-DIOXANES USEFUL AS PPAR MODULATORS | PPARD, PPARG, PPARA | FFAR1 13/4885ELANE 3295/4885CYP19A1 275/4885 |
| US-20150158838-A1 | Prodrugs of Substituted 1,3-Dioxanes and Their Uses | TBXA2R, PPARG, PPARA | FFAR1 25/4885ELANE 1101/4885CYP19A1 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.